Thiamet G
Thiamet G structure
|
Common Name | Thiamet G | ||
|---|---|---|---|---|
| CAS Number | 1009816-48-1 | Molecular Weight | 248.299 | |
| Density | 1.8±0.1 g/cm3 | Boiling Point | 483.2±55.0 °C at 760 mmHg | |
| Molecular Formula | C9H16N2O4S | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 246.0±31.5 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice.
Molecular Neurodegeneration 9 , 42, (2014) Amyloid plaques and neurofibrillary tangles (NFTs) are the defining pathological hallmarks of Alzheimer's disease (AD). Increasing the quantity of the O-linked N-acetylglucosamine (O-GlcNAc) post-translational modification of nuclear and cytoplasmic proteins ... |
|
|
Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation.
Nat. Chem. Biol. 8(4) , 393-9, (2012) Oligomerization of tau is a key process contributing to the progressive death of neurons in Alzheimer's disease. Tau is modified by O-linked N-acetylglucosamine (O-GlcNAc), and O-GlcNAc can influence tau phosphorylation in certain cases. We therefore speculat... |
|
|
A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo.
.PubMed ID Pathological hyperphosphorylation of the microtubule-associated protein tau is characteristic of Alzheimer's disease (AD) and the associated tauopathies. The reciprocal relationship between phosphorylation and O-GlcNAc modification of tau and reductions in O-... |